Clinical trial
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic…
NCT00237887 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00237887 |
|---|---|
| Title | Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| Official title | A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | adalimumab |
| Enrollment | 1,212 |
| Start date | Dec 1, 2004 |
| First posted | Oct 13, 2005 |
| Last update posted | Aug 29, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: